MannKind Corporation (MNKD) News
Filter MNKD News Items
MNKD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNKD News Highlights
- For MNKD, its 30 day story count is now at 2.
- Over the past 11 days, the trend for MNKD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MNKD are CONN, DEC and LUNG.
Latest MNKD News From Around the Web
Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, Ca |
Insider Sell: CEO Michael Castagna Offloads 200,482 Shares of MannKind Corp (MNKD)In a significant move within the pharmaceutical industry, CEO Michael Castagna has parted with a substantial number of shares in MannKind Corp (NASDAQ:MNKD). |
High-Yield Haven: 3 Dividend Stocks to Secure NowThese are three different dividend stocks that have a great dividend yield and offer a reliable source of income. |
Investors in MannKind (NASDAQ:MNKD) have seen solid returns of 115% over the past five yearsIt hasn't been the best quarter for MannKind Corporation ( NASDAQ:MNKD ) shareholders, since the share price has fallen... |
MannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call TranscriptMannKind Corporation (NASDAQ:MNKD) Q3 2023 Earnings Call Transcript November 7, 2023 MannKind Corporation beats earnings expectations. Reported EPS is $0.01, expectations were $-0.02. Operator: Good afternoon and welcome to the MannKind Corporation 2023 Third Quarter Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2023, and will be available […] |
MannKind (MNKD) Q3 2023 Earnings Call TranscriptAs a reminder, this call is being recorded on November 7, 2023, and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call until November 21, 2023. Joining us today from MannKind are Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder. |
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
MannKind Corporation Reports 2023 Third Quarter Financial ResultsConference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net income of $4M3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q 20223Q 2023 Endocrine BU net revenues of $18M; Afrezza net revenues +24% vs. 3Q 2022 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the |
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesRapidly enrolled 141 patients in less than four monthsLarge study will compare A1c from baseline to 17 weeks for adults when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Initial standardized meal data from INHALE-3 on target for presenting in 1Q 2024 followed by primary endpoint analysis in 2Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on th |
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseBiogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |